{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:13:53Z","timestamp":1772032433887,"version":"3.50.1"},"reference-count":78,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008175","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T16:00:18Z","timestamp":1256140818000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vitamin D compounds for people with chronic kidney disease not requiring dialysis"],"prefix":"10.1002","author":[{"given":"Suetonia C","family":"Palmer","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School; Renal Division; Harvard Institute of Medicine, Room 550 4 Blackfan Street Boston MA USA 02115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David O","family":"McGregor","sequence":"additional","affiliation":[{"name":"Christchurch Hospital; Department of Nephrology; Private Bag 4710 Christchurch New Zealand 8001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Sydney; Centre for Kidney Research, The Children's Hospital at Westmead; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grahame","family":"Elder","sequence":"additional","affiliation":[{"name":"Garvan Institute of Medical Research; Bone and Mineral Program; 384 Victoria St Darlinghurst NSW Australia 2010"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Macaskill","sequence":"additional","affiliation":[{"name":"School of Public Health; Screening and Test Evaluation Program (STEP); University of Sydney Edward Ford Building, A27 Sydney NSW Australia 2006"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD008175-BIB0002|cit1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s004670000365","article-title":"Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure","volume":"14","author":"Ardissino","year":"2000","journal-title":"Pediatric Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD008175-BIB0001|cit2","first-page":"562A","article-title":"Growth and PTH in children treated with daily vs intermittent oral calcitriol for secondary hyperparathyroidism. Preliminary results [abstract]","volume":"9","author":"Ardissino","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008175-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney International"},{"issue":"27","key":"10.1002\/14651858.CD008175-BIB0004|cit4","first-page":"S140","article-title":"Early therapy of renal bone disease with calcitriol: a prospective double-blind study","volume":"36","author":"Baker","year":"1989","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD008175-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jbmr.5650100205","article-title":"Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone","volume":"10","author":"Birkenhager-Frenkel","year":"1995","journal-title":"Journal of Bone & Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0022-3476(05)83128-2","article-title":"A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators","volume":"124","author":"Chan","year":"1994","journal-title":"Journal of Pediatrics"},{"issue":"1B","key":"10.1002\/14651858.CD008175-BIB0010|cit7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0022-4731(83)90212-1","article-title":"Chronic renal failure and vitamin D metabolites","volume":"19","author":"Christiansen","year":"1983","journal-title":"Journal of Steroid Biochemistry"},{"issue":"3","key":"10.1002\/14651858.CD008175-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2265.1981.tb00659.x","article-title":"Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure?","volume":"15","author":"Christiansen","year":"1981","journal-title":"Clinical Endocrinology"},{"issue":"8092 Pt 1","key":"10.1002\/14651858.CD008175-BIB0007|cit9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(78)92702-2","article-title":"Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol","volume":"2","author":"Christiansen","year":"1978","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008175-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000403281","article-title":"Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure","volume":"18","author":"Christiansen","year":"1980","journal-title":"Contributions to Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008175-BIB0012|cit12","first-page":"117","article-title":"Treatment with small doses of 1,25-dihydroxyvitamin D3 in predialysis chronic renal failure may lower the rate of decline of renal function","volume":"8","author":"Coen","year":"1994","journal-title":"Italian Journal of Mineral and Electrolyte Metabolism"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0013|cit13","first-page":"734A","article-title":"Paricalcitol (Zemplar(R)) capsule dosed with daily or three times a week regimen is equally effective in reducing iPTH levels in CKD stage 3-4 patients [abstract]","volume":"15","author":"Abboud","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000092033","article-title":"A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4","volume":"26","author":"Abboud","year":"2006","journal-title":"American Journal of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0015|cit15","first-page":"734A","article-title":"Safety experience of paricalcitol (Zemplar (R)) capsule in phase 3 trials in CKD stages 3 and 4 patients with secondary hyperparathyroidism (SHPT) [abstract]","volume":"15","author":"Acharya","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0016|cit16","first-page":"734A","article-title":"Paricalcitol (Zemplar (R)) capsule reduced elevated iPTH levels significantly in CKD stages 3 and 4 patients regardless of race, gender, age, disease severity and diabetic status [abstract]","volume":"15","author":"Cheek","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD008175-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0018|cit18","first-page":"733A","article-title":"Paricalcitol (Zemplar (R)) capsule controls secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) stages 3 and 4 patients. [abstract]","volume":"15","author":"Coyne","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0019|cit19","first-page":"862A","article-title":"No increase in hypercalcemia episode with paricalcitol (Zemplar (R)) capsule therapy regardless of concomitant calcium-based phosphate binder in CKD stages 3 and patients. [abstract]","volume":"15","author":"Levine","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD008175-BIB0020|cit20","first-page":"734A","article-title":"Achievement of NKF-K\/DOQITM bone metabolism and disease targets with paricalcitol (Zemplar (R)) therapy [abstract]","volume":"15","author":"Norris","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6976","key":"10.1002\/14651858.CD008175-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0022|cit22","first-page":"172","article-title":"Treatment of predialysis renal bone disease (RBD) with 1alpha (OH) vitamin D3 and 1,25-(OH) 2 vitamin D3","volume":"22","author":"Juttmann","year":"1979","journal-title":"Netherlands Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","volume":"67","author":"Nordal","year":"1988","journal-title":"Journal of Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0024|cit24","first-page":"206","article-title":"Calcitriol therapy in predialytic secondary hyperparathyroidism: Effects of oral pulses versus a daily oral regimen","volume":"8","author":"Panichi","year":"1995","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0025|cit25","first-page":"245","article-title":"Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure","volume":"49","author":"Panichi","year":"1998","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD008175-BIB0026|cit26","first-page":"A46","article-title":"Oral calcitriol in predialytic hyperparathyroidism. Comparison of three different therapeutic schedules [abstract]","volume":"11","author":"Panichi","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"issue":"12","key":"10.1002\/14651858.CD008175-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","article-title":"Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)","volume":"10","author":"Ritz","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7968","key":"10.1002\/14651858.CD008175-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0140-6736(76)92220-0","article-title":"Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure","volume":"1","author":"Tougaard","year":"1976","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008175-BIB0031|cit31","unstructured":"Comparison of cholecalciferol versus doxercalciferol in the treatment of secondary hyperparathyroidism in chronic kidney disease stage three and four http:\/\/www.clinicaltrials.gov\/ (accessed August 2009)"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","article-title":"Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation","volume":"69","author":"Andress","year":"2006","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008175-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008175-BIB0036|cit36","first-page":"117","article-title":"Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells","volume":"23 Suppl 2","author":"Cardus","year":"2003","journal-title":"Nefrologia"},{"issue":"8","key":"10.1002\/14651858.CD008175-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.ki.5000304","article-title":"1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway","volume":"69","author":"Cardus","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000057611","article-title":"Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH","volume":"91","author":"Coen","year":"2002","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CNP59059","article-title":"Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy","volume":"59","author":"Leo","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"6964","key":"10.1002\/14651858.CD008175-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7109","key":"10.1002\/14651858.CD008175-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"25","key":"10.1002\/14651858.CD008175-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008175-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"Journal of American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000190244","article-title":"Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis","volume":"77","author":"Goldsmith","year":"1997","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/01.hjh.0000166849.72721.1c","article-title":"Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3","volume":"23","author":"Haffner","year":"2005","journal-title":"Journal of Hypertension"},{"issue":"7414","key":"10.1002\/14651858.CD008175-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD008175-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","article-title":"IIn subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3","volume":"18","author":"Hirata","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"H1942","DOI":"10.1152\/ajpheart.00091.2006","article-title":"Ventricular arterial coupling in a rat model of reduced arterial compliance provoked by hypervitaminosis D and nicotine","volume":"291","author":"Jegger","year":"2006","journal-title":"American Journal of Physiology - Heart & Circulatory Physiology"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney International"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD008175-BIB0051|cit51","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Disease"},{"issue":"2","key":"10.1002\/14651858.CD008175-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD008175-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovedsy","year":"2008","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008175-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archneur.1980.00500580051007","article-title":"Proximal muscle weakness in uremia. Case reports and review of the literature","volume":"37","author":"Lazaro","year":"1980","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jrn.2006.07.006","article-title":"Impact of kidney bone disease and its management on survival of patients on dialysis","volume":"17","author":"Lee","year":"2007","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD008175-BIB0057|cit57","unstructured":"Lefebvre C McDonald S Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia) 1996"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD008175-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1681\/ASN.2005040342","article-title":"Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol","volume":"17","author":"Lopez","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD008175-BIB0060|cit60","unstructured":"United States Cochrane Center Master list of journals being searched http:\/\/apps1.jhsph.edu\/cochrane\/masterlist.asp (accessed May 2009)"},{"issue":"3","key":"10.1002\/14651858.CD008175-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub3","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","author":"Palmer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9559","key":"10.1002\/14651858.CD008175-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008175-BIB0064|cit64","first-page":"57","article-title":"Fractures and vertebral bone mineral density in patients with renal osteodystrophy","volume":"30","author":"Piraino","year":"1988","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD008175-BIB0065|cit65","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 3. Art. No.: RENAL (accessed July 2009)"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1523-1755.2005.00693.x","article-title":"Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time","volume":"68","author":"Robinson","year":"2005","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD008175-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD008175-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD008175-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","article-title":"Efficacy of 19-nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008175-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD008175-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD008175-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"Journal of the Amercian Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.106.101261","article-title":"Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification","volume":"318","author":"Wu-Wong","year":"2006","journal-title":"Journal of Pharmacology & Experimental Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008175-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD008175-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005633","article-title":"Vitamin D analogues for the treatment and prevention of bone disease in chronic kidney disease","author":"Palmer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008175-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: Vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Annals of Internal Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008175\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T14:37:03Z","timestamp":1634049423000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008175"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008175","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}